Sexually transmitted infection
Leading-edge, patient-centric testing
Testing for sexually transmitted infections, or STIs, is essential for sexually active individuals with more than one sexual partner. Many STIs, which can be caused by bacteria, viruses, and parasites, often have no initial symptoms, but can lead to serious health concerns. Early detection can help identify appropriate treatment and limit harm.
Mayo Clinic Laboratories offers a full suite of testing for STIs, including self-collection options for chlamydia, gonorrhea, and human papillomavirus (HPV). We also offer a unique-to-the-market, treponemal-based antibody index to identify and confirm neurosyphilis.
Supported by data and built around the needs of patients, our assays are developed by experienced laboratory physicians and scientists who possess expertise in all areas of testing for conventional and molecular microbiology.
Test menu
Chlamydia and gonorrhea
Our full menu of advanced testing for chlamydia and gonorrhea infections, including self-collection and combination molecular testing.
Hepatitis B and C screening
We offer a full range of screening evaluations for hepatitis B and hepatitis C, including prenatal testing for expectant mothers.
Human immunodeficiency virus (HIV)
Our full menu of HIV-1 and HIV-2 testing includes screening, diagnostic, and confirmatory testing. Guided by an algorithmic approach, our testing aligns with recommendations put forth by the U.S. Centers for Disease Control and Prevention (CDC).
Human papillomavirus (HPV)
Our menu of molecular HPV tests, which includes self-collect options, can clarify the specific subtype. Utilizing polymerase chain reaction (PCR), our assays offer high sensitivity and specificity for the detection and genotyping of HPV.
Neurosyphilis
Our highly sensitive and specific offering to confirm neurosyphilis is an IgG antibody index that detects intrathecal antibodies specific to the disease-causing agent Treponema pallidum. The treponemal-based assay, which is the only of its kind available in the U.S., offers a specificity of 85%–100% and sensitivity of 86%–90% to detect the neurological infection.